Free fatty acids are associated with insulin resistance but not coronary artery atherosclerosis in rheumatoid arthritis

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 869-874

  Ormseth, Michelle J ^a   Swift, Larry L ^a   Fazio, Sergio ^a   Linton, MacRae F ^a   Chung, Cecilia P ^a   Raggi, Paolo ^b   Rho, Young Hee ^a   Solus, Joseph ^c   Oeser, Annette ^a   Bian, Aihua ^a   Gebretsadik, Tebeb ^a   Shintani, Ayumi ^a   Michael Stein, C ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Free fatty acids; Insulin resistance; Rheumatoid arthritis

Indexed keywords

CALCIUM; FATTY ACID; INTERLEUKIN 6; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPOTHESIS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RHEUMATOID ARTHRITIS;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FATTY ACIDS, NONESTERIFIED; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; INTERLEUKIN-6; LINEAR MODELS; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 82955182182     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.005     Document Type: Article

References (38)

1. Chung C.P., Oeser A., Raggi P., et al. Increased coronary artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005, 52:3045-3053.
2. Chung C.P., Oeser A., Solus J.F., et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008, 58:2105-2112.
3. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008, 37:635.
4. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997, 46:3-10.
5. Boden G., Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995, 96:1261-1268.
6. Dresner A., Laurent D., Marcucci M., et al. Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999, 103:253-259.
7. Jensen M.D., Haymond M.W., Rizza R.A., et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989, 83:1168-1173.
8. Inoguchi T., Li P., Umeda F., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependant activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49:1939-1945.
9. Chinen I., Shimabukuro M., Yamakawa K., et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007, 148:160-165.
10. Boden G., She P., Mozzoli M., et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κß pathway in the rat liver. Diabetes 2005, 54:3458-3465.
11. Tripathy D., Mohanty P., Dhindsa S., et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003, 52:2882-2887.
12. Green A., Dobias S.B., Walters D.J., et al. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology 1994, 134:2581-2588.
13. Souza S.C., Yamamoto M.T., Franciosa M.D., et al. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-α - a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes 1998, 47:691-695.
14. Yang R., Lee M., Hu H., et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PloS Med 2006, 3:e287.
15. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
16. Agatston A.S., Janowitz W.R., Hildner F.J., et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990, 15:827-832.
17. Prevoo M.L., van't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
18. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
19. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:413-419.
20. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735.
21. Rho Y.H., Chung C.P., Oeser A., et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009, 61:1580-1585.
22. Chung C.P., Oeser A., Solus J.F., et al. Prevalence of metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008, 196:756-763.
23. Kawakami M., Murase T., Ogawa H., et al. Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-l1 cells. J Biochem 1987, 101:331-338.
24. Mattacks C.A., Pond C.M. Interactions of noradrenalin and tumor necrosis factor alpha, interleukin 4 and interleukin 6 in the control of lipolysis from adipocytes around lymph nodes. Cytokine 1999, 11:334-346.
25. Van der Poll T., Romijn J.A., Wiersinga W.M., Sauerwein H.P. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 1990, 71:1567-1572.
26. vanHall G., Steensberg A., Sacchettu M., et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endo Metab 2003, 88:3005-3010.
27. Heinrick P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem J 1990, 265:621-636.
28. Dvorakova-Lorenzova A., Suchanek P., Havel P.J., et al. The decrease in C-reactive protein concentration after diet and physical activity induced weight reduction is associated with changes in plasma lipids, but not interleukin-6 or adiponectin. Metab Clin Exp 2006, 55:359-365.
29. Pradhan A.D., Manson J.E., Rossouw J.E., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002, 288:980-987.
30. Gomez F., Jequier E., Chabot V., et al. Carbohydrate and lipid oxidation in normal human subjects: its influence on glucose tolerance and insulin response to glucose. Metabolism 1972, 21:381-391.
31. Santomauro A.T.M.G., Boden G., Silva M.E.R., et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999, 48:1836-1841.
32. Steinberg H.O., Baron A.D. Vascular function, insulin resistance and fatty acids. Diabetologia 2002, 45:623-634.
33. Steinberg H.O., Tarshoby M., Monestel R., et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997, 100:1230-1239.
34. Mathew M., Tay E., Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 2010, 9:9.
35. Ishiyama J., Taguchi R., Yamamoto A., Murakami K. Palmitic acid enhances lectin-like oxidized LDL receptor (LOX-1) expression and promotes uptake of oxidized LDL in macrophage cells. Atherosclerosis 2010, 209:118-124.
36. Taniguchi A., Nakai Y., Fukushima M., et al. Ultrasonography assessed carotid atherosclerosis in Japanese type 2 diabetic patients: role of non-esterified fatty acids. Metabolism 2002, 51:539-543.
37. Armstrong K.A., Hiremagalur B., Haluska B.A., et al. Free fatty acids are associated with obesity, insulin resistance, and atherosclerosis in renal transplant recipients. Transplantation 2005, 80:937-944.
38. Fontana L., Eagon C., Trujillo M.E., et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.